Recent data “concerning treatment with cladribine demonstrate three important aspects. The first is related to effectiveness. We have seen, in fact, that the therapy is effective in reducing inflammatory activity, but also in the progression of long-term disability. The second aspect, equally important, is linked to safety. Cladribine is a therapy that essentially presents no surprises from the safety point of view. The third aspect concerns the quality of life: the patient, if on oral treatment, with just a few tablets , as in this case, for a limited period of time, he can almost forget that he is being treated.” Thus Claudio Gasperini, medical director of the Neuroscience Department of the San Camillo-Forlanini hospital in Rome, on the sidelines of the first of the two days 'Space of care: as one for patients', an event organized in Milan by the global pharmaceutical company Merck and dedicated to new therapeutic frontiers for the treatment of highly active relapsing multiple sclerosis, among which cladribine in tablets stands out.
“The issue that must be asked – underlines the expert – is how long this therapy can be used, because we know that the guidelines allow us to treat the patient for 2 years. The Italian Neurology Society, for example, is expressing itself on this aspect as we are increasingly moving towards personalized treatment – specifies Gasperini – From real world studies, also conducted in other countries, data is emerging which shows us how cladribine, also used with a third cycle, can lead benefits from an effectiveness point of view, without increasing the safety problem, for a long period of time”.
“We hope that, in the context of personalized therapy – concludes the neurologist – there will be the possibility for us neurologists to be able to use the drug even beyond 2 years, which is the period of time for which it is administered in clinical practice today” .
#Multiple #sclerosis #neurologist #Gasperini #Cladribine #reduces #inflammatory #activity
